- GlobeNewswire•10 days agoINNATE PHARMA: Preliminary safety and clinical activity results for IPH4102 to be presented at the Third World Congress of Cutaneous Lymphomas
MARSEILLE, France -- Innate Pharma SA (the "Company" - Euronext Paris: FR0010331421 - IPH), today announces that preliminary safety and clinical activity results for the Phase I study testing ...
- GlobeNewswire•15 days agoSafety Data for Lirilumab in Combination with Nivolumab or Ipilimumab Announced at ESMO 2016 Congress
The combination of lirilumab and nivolumab in a phase I study of advanced solid tumors showed no added toxicity over nivolumab monotherapy;
- Business Wire•15 days agoSafety Data for Lirilumab in Combination with Nivolumab or Ipilimumab Announced at ESMO 2016 Congress
Bristol-Myers Squibb Company and Innate Pharma SA today announced safety data for two Phase I studies conducted by Bristol-Myers Squibb, testing lirilumab in combination with nivolumab or ipilimumab, respectively, in patients with advanced refractory solid tumors.
Innate Pharma S.A. (IPH.PA)
Paris - Paris Delayed Price. Currency in EUR
|Bid||10.52 x 100000|
|Ask||10.66 x 4600|
|Day's Range||10.51 - 10.67|
|52wk Range||8.26 - 15.19|
|1y Target Est||N/A|
|P/E Ratio (ttm)||-263.75|
|Avg Vol (3m)||274,884|
|Dividend & Yield||N/A (N/A)|